Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Peter MacCallum Cancer Center, East Melbourne

Royal Melbourne Hospital, Parkville

Monash Health, Monash Medical Centre, Clayton

Royal Adelaide Hospital, Adelaide

Mount Sinai Medical Center, New York

Columbia University Medical Center, New York

New York Presbyterian Hospital-Weill Cornell Medical College, New York

Montefiore Medical Center, The Bronx

Institute Paoli Calmettes, Marseille

Greenbaum Cancer Center University of Maryland, Baltimore

AOU Maggiore della Carità, SCUD Ematologia, Novara

Hospital Universitário de Salamanca, Salamanca

Universitätsmedizin Göttingen, Göttingen

Marien Hospital, Onkologie, Düsseldorf

Sahlgrenska University Hospital, Gothenberg

Azienda Ospedaliero-Universitaria Careggi, Florence

Universitätsklinikum Köln Klinik I für Innere Medizin, Cologne

Mayo Clinic, Rochester

Universitätsklinikum Frankfurt, Goethe Universität, Frankfurt am Main

Rush University Medical Center, Chicago

University of Chicago Medicine, Chicago

University of Kansas Cancer Center and Medical Pavilion, Westwood

University of Texas Southwestern Medical Center-Parkland Hospital, Dallas

University of Texas Southwestern Medical Center, Dallas

Hôpital Saint-Louis, Service d'Hématologie, Paris

MD Anderson Cancer Center, Houston

Technische Universität München, III. Medizinische Klinik, München

Stanford University Cancer Center, Stanford

Dana Farber Cancer Institute, Boston

Rigshospitalet, Department of Hematology, Copenhagen

Aarhus University Hospital, Aarhus

University Hospital Carl Guslav Carus, Dresden

"Policlinico Umberto 1, Universita Sapienza", Rome

Skåne University Hospital,, Lund

Karolinska University Hospital, Huddinge, Stockholm